From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC-Reference-Cited by-同舟云学术

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC

Published:2019-05 Issue: Volume:131 Page:78-85
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Bordi Paola^ORCID,Del Re Marzia^ORCID,Minari Roberta^ORCID,Rofi Eleonora,Buti Sebastiano^ORCID,Restante Giuliana^ORCID,Squadrilli Anna,Crucitta Stefania^ORCID,Casartelli Chiara,Gnetti Letizia,Azzoni Cinzia,Bottarelli Lorena,Petrini Iacopo^ORCID,Cosenza Agnese,Ferri Leonarda,Rapacchi Elena,Danesi Romano,Tiseo Marcello

Funder

AIRC

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. ESMO Guidelines Committee, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann. Oncol.,2018

2. EGFR-mutated lung cancer: a paradigm of molecular oncology;Zhang;Oncotarget,2010

3. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib;Kobayashi;N. Engl. J. Med.,2005

4. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor;Finlay;J. Med. Chem.,2014

5. Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer;Mok;N. Engl. J. Med.,2017

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies;Critical Reviews in Oncology/Hematology;2024-04

2. The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis;The Clinical Respiratory Journal;2024-04

3. Detection of EGFR T790M mutation using liquid biopsy for non-small cell lung cancer: Utility of droplet digital polymerase chain reaction vs. cobas real-time polymerase chain reaction;Pathology - Research and Practice;2024-03

4. Liquid biopsy for the management of NSCLC patients under osimertinib treatment;Critical Reviews in Clinical Laboratory Sciences;2024-02-02

5. MYC expression and fatty acid oxidation in EGFR-TKI acquired resistance;Drug Resistance Updates;2024-01